Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19

Clin Microbiol Infect. 2023 May;29(5):660-662. doi: 10.1016/j.cmi.2023.01.016. Epub 2023 Jan 23.

Authors

Giulia Marchetti¹, Roberta Rovito², Valeria Bono², Paola Bonara³, Francesca Bai², Antonella d'Arminio Monforte²

Affiliations

¹ Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy. Electronic address: [email protected].
² Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy.
³ Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
COVID-19 Drug Treatment
COVID-19*
Humans
Ritonavir / therapeutic use

Substances

nirmatrelvir
Ritonavir
Antiviral Agents